Atsena Therapeutics Reported Positive Gene Therapy Results
The company shared 18-month clinical data for its gene therapy targeting an inherited cause of blindness.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Should medical research prioritize funding gene therapies for rare vision loss conditions?
Atsena Therapeutics presented 18-month safety and efficacy results for its ATSN-201 gene therapy at the American Academy of Optometry 2026 Annual Meeting. The trial indicated significant vision improvements and foveal schisis closure in patients with X-linked retinoschisis.
Why it matters
X-linked retinoschisis is an inherited condition that leads to progressive vision loss and blindness, currently lacking effective long-term treatments. These results represent a significant milestone in validating a gene therapy approach for restoring retinal structure.
The study involved 9 adult patients receiving subretinal injections of the AAV.SPR capsid. Treated eyes achieved 10-letter visual acuity improvements in 7 out of 9 cases, with 6 out of 9 eyes showing microperimetry gains of 7 dB or greater.
The players
Atsena Therapeutics
Atsena Therapeutics is a clinical-stage biotech company headquartered in Durham, N.C. that develops novel gene therapies for inherited retinal diseases.
American Academy of Optometry
The American Academy of Optometry is a professional organization that holds annual meetings to discuss advancements in eye care and vision science.
The details
ATSN-201 uses the AAV.SPR capsid designed to target photoreceptors in the central retina, allowing the therapy to spread laterally through subretinal injection. The clinical trial reported no drug-related serious adverse events or dose-limiting toxicities among participants.
Timeline
September 30 - October 3, 2026: Results were presented at the Annual Meeting.
June 2026: The pivotal Part C cohort began the dosing process.
Q1 2027: Enrollment for the Part C cohort is scheduled to finish.
1H 2028: Topline results for the Part C study are expected to be released.
2H 2028: The company targets a BLA filing for the therapy.
The Tech Race
The success of ATSN-201 demonstrates the industry's shift toward using engineered capsids like AAV.SPR to improve targeted delivery to the central retina. This approach aims to replace traditional, less precise viral vectors that struggle to achieve lateral spread in the eye.
For patients suffering from X-linked retinoschisis, this therapy offers a potential breakthrough to prevent permanent vision loss. If approved, the treatment could provide a new medical option to restore visual acuity and stabilize retinal health for those affected.
The takeaway
Gene therapy continues to show promise as a targeted approach for treating complex inherited retinal conditions. Patients and families should monitor future trial phases as researchers move closer to commercial approval timelines.
What happens next
Atsena Therapeutics plans to complete enrollment for the pivotal Part C cohort by the end of Q1 2027, followed by the release of topline results in the first half of 2028 and a targeted BLA filing in the second half of 2028.
Further reading
Learn more about the latest developments in the Biotech sector.
Source note: This article includes information reported by The Manila times.
Live Poll
Should medical research prioritize funding gene therapies for rare vision loss conditions?
